Diagnostic performance of noninvasive imaging using computed tomography, magnetic resonance imaging, and positron emission tomography for the detection of ovarian cancer: a meta-analysis
- PMID: 37422857
- DOI: 10.1007/s12149-023-01856-7
Diagnostic performance of noninvasive imaging using computed tomography, magnetic resonance imaging, and positron emission tomography for the detection of ovarian cancer: a meta-analysis
Abstract
Objective: The aim of this meta-analysis was to compare the diagnostic value of noninvasive imaging methods computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) in the detection of ovarian cancer (OC).
Methods: PubMed, Embase, and Ovid were comprehensively searched from the date of inception to 31st, March, 2022. Pooled sensitivity, specificity, positive likelihood ratio (+ LR), negative likelihood ratio (- LR), diagnostic odds ratio (DOR), and area under the curve (AUC) of summary receiver operating characteristic (SROC) with their respective 95% confidence intervals (CIs) were calculated.
Results: Sixty-one articles including 4284 patients met the inclusion criteria of this study. Pooled estimates of sensitivity, specificity, and AUC of SROC with respective 95% CIs of CT on patient level were 0.83 (0.73, 0.90), 0.69 (0.54, 0.81), and 0.84 (0.80, 0.87). The overall sensitivity, specificity, SROC value with respective 95% CIs of MRI were 0.95 (0.91, 0.97),0.81 (0.76, 0.85), and 0.90 (0.87, 0.92) on patient level. Pooled estimates of sensitivity, specificity, SROC value of PET/CT on patient level were 0.92 (0.88, 0.94), 0.88 (0.83, 0.92), and 0.96 (0.94, 0.97).
Conclusion: Noninvasive imaging modalities including CT, MRI, PET (PET/CT, PET/MRI) yielded favorable diagnostic performance in the detection of OC. Hybrid implement of different tools (PET/MRI) is more accurate for identifying metastatic OC.
Keywords: CT; Diagnostic performance; MRI; Meta-analysis; Ovarian cancer; PET.
© 2023. The Author(s) under exclusive licence to The Japanese Society of Nuclear Medicine.
Similar articles
-
Staging/restaging performance of F18-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in breast cancer: A review and meta-analysis.Eur J Radiol. 2018 Oct;107:158-165. doi: 10.1016/j.ejrad.2018.09.003. Epub 2018 Sep 5. Eur J Radiol. 2018. PMID: 30292261
-
Diagnostic performance of MRI, SPECT, and PET in detecting renal cell carcinoma: a systematic review and meta-analysis.BMC Cancer. 2022 Feb 11;22(1):163. doi: 10.1186/s12885-022-09239-3. BMC Cancer. 2022. PMID: 35148700 Free PMC article.
-
Fluorine-18 deoxyglucose positron emission tomography, magnetic resonance imaging and bone scintigraphy for the diagnosis of bone metastases in patients with lung cancer: which one is the best?--a meta-analysis.Clin Oncol (R Coll Radiol). 2011 Jun;23(5):350-8. doi: 10.1016/j.clon.2010.10.002. Epub 2010 Nov 20. Clin Oncol (R Coll Radiol). 2011. PMID: 21094027
-
Diagnostic performance of computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with cervical cancer: meta-analysis.Cancer Sci. 2010 Jun;101(6):1471-9. doi: 10.1111/j.1349-7006.2010.01532.x. Epub 2010 Feb 11. Cancer Sci. 2010. PMID: 20298252 Free PMC article.
-
18F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis.Acta Radiol. 2012 Jul;53(6):615-27. doi: 10.1258/ar.2012.110603. Epub 2012 Jun 25. Acta Radiol. 2012. PMID: 22734080
Cited by
-
Comparison of 68Ga-FAPI-04 and 18F-FDG PET/CT in diagnosing ovarian cancer.Abdom Radiol (NY). 2024 Dec;49(12):4531-4542. doi: 10.1007/s00261-024-04469-4. Epub 2024 Jun 27. Abdom Radiol (NY). 2024. PMID: 38937339
-
18F-Fluoro-2-Deoxyglucose Positron Emission Tomography/Computed Tomography Measures of Spatial Heterogeneity for Predicting Platinum Resistance of High-Grade Serous Ovarian Cancer.Cancer Med. 2024 Oct;13(20):e70287. doi: 10.1002/cam4.70287. Cancer Med. 2024. PMID: 39435561 Free PMC article.
-
Survival time prediction in patients with high-grade serous ovarian cancer based on 18F-FDG PET/CT- derived inter-tumor heterogeneity metrics.BMC Cancer. 2024 Mar 12;24(1):337. doi: 10.1186/s12885-024-12087-y. BMC Cancer. 2024. PMID: 38475819 Free PMC article.
-
Diagnostic Value of PET/CT for Ovarian Cancer Recurrence or Metastasis in Postoperative Patients With Elevated Serum CA125 Levels: A Systematic Review and Meta-Analysis.Cancer Innov. 2025 Jun 2;4(4):e70015. doi: 10.1002/cai2.70015. eCollection 2025 Aug. Cancer Innov. 2025. PMID: 40463490 Free PMC article.
-
Future theranostic strategies: emerging ovarian cancer biomarkers to bridge the gap between diagnosis and treatment.Front Drug Deliv. 2024 Feb 1;4:1339936. doi: 10.3389/fddev.2024.1339936. eCollection 2024. Front Drug Deliv. 2024. PMID: 40836974 Free PMC article. Review.
References
-
- Stewart C, Ralyea C, Lockwood S. Ovarian cancer: an integrated review. Semin Oncol Nurs. 2019;35(2):151–6. - PubMed
-
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. - PubMed
-
- Virarkar M, Ganeshan D, Gulati AT, Palmquist S, Iyer R, Bhosale P. Diagnostic performance of PET/CT and PET/MR in the management of ovarian carcinoma-a literature review. Abdominal Radiol. 2021;46(6):2323–49.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous